In a report released today, David Westenberg from Piper Sandler maintained a Hold rating on Myriad Genetics (MYGN – Research Report), with a price target of $23.00. The company’s shares closed yesterday at $22.23.
According to TipRanks, Westenberg is a 3-star analyst with an average return of 1.1% and a 46.31% success rate. Westenberg covers the Healthcare sector, focusing on stocks such as Myriad Genetics, Natera, and Illumina.
In addition to Piper Sandler, Myriad Genetics also received a Hold from TD Cowen’s Daniel Brennan in a report issued on February 28. However, on the same day, J.P. Morgan maintained a Sell rating on Myriad Genetics (NASDAQ: MYGN).
See Insiders’ Hot Stocks on TipRanks >>
Based on Myriad Genetics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $191.9 million and a GAAP net loss of $61.3 million. In comparison, last year the company earned a revenue of $156.4 million and had a GAAP net loss of $35.1 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Myriad Genetics (MYGN) Company Description:
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to asses an individual’s risk of developing a disease later in life. The Other segment offers products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients; and also includes corporate services such as finance, human resources, legal, and information technology. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.
Read More on MYGN:
- Myriad Genetics price target raised to $28 from $25 at Raymond James
- Myriad Genetics price target raised to $26 from $23 at TD Cowen
- Myriad Genetics price target raised to $17 from $14 at JPMorgan
- Myriad Genetics sees FY24 adjusted EPS 0c-5c, consensus (1c)
- Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance
